Nuformix Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	4yrs

Recent management updates

Recent updates

CEO

Nuformix has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Daniel Gooding	Executive Director	2.3yrs	UK£30.00k	4.58% € 25.6k
Julian Gilbert	Senior Independent Non-Executive Chairman	4yrs	UK£51.00k	0.031% € 170.9
Alan Chorlton	Member of Scientific Advisory Board	no data	no data	no data
Chris Frampton	Member of Scientific Advisory Board	no data	no data	no data
Andy Richards	Chairman of Advisory Panel	6.9yrs	no data	no data
Derek Mann	Member of Advisory Panel	5.9yrs	no data	no data
Jeffery Lindeman	Member of Advisory Board	no data	no data	no data
Madeleine Kennedy	Independent Non-Executive Director	3.9yrs	UK£51.00k	0.031% € 170.9

4.0yrs

Average Tenure

59yo

Average Age

Experienced Board: 1RT's board of directors are considered experienced (4 years average tenure).

Nuformix Management

Management criteria checks 1/4

Key information

Recent management updates

Nuformix plc, Annual General Meeting, Mar 19, 2024

Nuformix plc, Annual General Meeting, Aug 24, 2023

Nuformix plc, Annual General Meeting, Aug 25, 2022

Nuformix plc Announces Board Changes, Effective August 1, 2022

Nuformix plc Announces Directorate Change

Nuformix plc Announces Resignation of Chris Blackwell as Non-Executive Chairman and Director

Recent updates

New major risk - Financial position

Nuformix plc has completed a Follow-on Equity Offering in the amount of £0.15 million.

Nuformix plc has filed a Follow-on Equity Offering in the amount of £0.15 million.

Nuformix plc has filed a Follow-on Equity Offering in the amount of £0.15 million.

New minor risk - Financial data availability

Nuformix plc, Annual General Meeting, Mar 19, 2024

New minor risk - Financial data availability

Nuformix plc Announces Notice of Allowance of NXP002 Patent in Japan

Nuformix plc, Annual General Meeting, Aug 24, 2023

Nuformix plc Announces Update Regarding the NXP002 Programme

Nuformix plc Announces NXP004 Update

Nuformix plc Announces Update Regarding the Company's NXP002 Programme, A Proprietary New Form of Tranilast, Being Developed as A Novel Inhaled Treatment for Idiopathic Pulmonary Fibrosis

Nuformix plc Announces NXP002 Completion of Tolerability Studies

Nuformix plc, Annual General Meeting, Aug 25, 2022

Full year 2022 earnings released: UK£0.002 loss per share (vs UK£0.002 loss in FY 2021)

Nuformix plc Announces Board Changes, Effective August 1, 2022

Nuformix plc Provides NXP004 Update

Nuformix plc Provides NXP002 Update

Nuformix plc Announces Directorate Change

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Nuformix plc Provides an Update on Its Lead Asset, NXP002

Full year 2021 earnings released: UK£0.002 loss per share (vs UK£0.002 loss in FY 2020)

Nuformix plc Announces Notice of Allowance of Patent in US

Nuformix plc Provides Project Update - Progress on NXP002 and NXP004

Senior Independent Director has left the company

Chief Scientific Officer & Director has left the company

Non-Executive Chairman Christopher Blackwell has left the company

Nuformix plc Announces Resignation of Chris Blackwell as Non-Executive Chairman and Director

CEO

Board Members

Average Tenure

Average Age